Terlipressin acetate 醋酸特利加压素|cas:1884420-36-3|西域试剂

Terlipressin acetate 醋酸特利加压素,99.76%

产品编号：Bellancom-12554A| CAS NO：1884420-36-3| 分子式：C₅₆H₈₂N₁₆O₁₉S₂| 分子量：1347.48

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-12554A	￥500.00	杭州北京（现货）
Bellancom-12554A	￥680.00	杭州北京（现货）
Bellancom-12554A	￥1250.00	杭州北京（现货）
Bellancom-12554A	￥1660.00	杭州北京（现货）
Bellancom-12554A	￥2650.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Terlipressin acetate 醋酸特利加压素

产品介绍

Terlipressin acetate 是一种具有血管活性的加压素类似物，也是一种高度选择性的加压素 V1 受体激动剂，可减少内脏血流量和门脉压力并控制急性静脉曲张破裂出血。Terlipressin acetate 具有抗炎和抗氧化作用，可用于肝肾综合征和耐去甲肾上腺素的败血性休克的研究。

生物活性

Terlipressin acetate is a vasopressin analogue with potent vasoactive properties. Terlipressin acetate is a highly selective vasopressin V1 receptor agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding. Terlipressin acetate exerts anti-inflammatory and anti-oxidative effects. Terlipressin acetate has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research^[4]^[5].

体外研究

Terlipressin (25 nM; 24-72 hours; IEC-6 cells) treatment significantly improves cell viability, proliferation and apoptosis in IEC-6 cells.
Terlipressin inhibits the secretion of TNF-α and 15-F2t-isoprostane from IEC-6 cells following oxygen and glucose deprivation/re-oxygenation (OGD/R). Terlipressin administration following OGD attenuates OGD/R-induced cell damage via the PI3K signaling pathway.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	IEC-6 cells induced by oxygen and glucose deprivation/re-oxygenation (OGD/R)
Concentration:	25 nM
Incubation Time:	24 hours, 48 hours, 72 hours
Result:	Significantly increased the proliferation of IEC-6 cells.

体内研究
(In Vivo)

Using a mouse nonlethal hepatic ischemia-reperfusion (IR) model, Terlipressin administration significantly ameliorates IR-induced liver apoptosis, necrosis and inflammation.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Using a mouse nonlethal hepatic ischemia-reperfusion (IR) model, Terlipressin administration significantly ameliorates IR-induced liver apoptosis, necrosis and inflammation.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Using a mouse nonlethal hepatic ischemia-reperfusion (IR) model, Terlipressin administration significantly ameliorates IR-induced liver apoptosis, necrosis and inflammation.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Solid

溶解性数据

In Vitro:

H₂O : 100 mg/mL (74.21 mM; Need ultrasonic)

DMSO : 50 mg/mL (37.11 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.7421 mL	3.7106 mL	7.4213 mL
5 mM	0.1484 mL	0.7421 mL	1.4843 mL
10 mM	0.0742 mL	0.3711 mL	0.7421 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： PBS
Solubility: 100 mg/mL (74.21 mM); Clear solution; Need ultrasonic
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (1.86 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (1.86 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (1.86 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (1.86 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。